Any attempt to deal exhaustively with my subject in a talk of under one hour must, I think, become an uninteresting and indeed indigestible catalogue of facts and figures. At the risk of doing less than justice to many interesting facets of pharmaceutical industry, I therefore propose to concentrate upon its major activities, to indicate how these are maintained in going order and to offer here and there a suggestion for their improvement.
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As I cannot avoid covering some of the subjects at present under consideration by members of the Joint Sub-Committee on Safety of Drugs, I must make it clear that my views are not Inecessarily those of my Company nor of the Trade Association of which I am an officer.
Definition
There is no completely satisfactory definition of this industry, but its growing points are covered by saying that it is the total activity of some fifty or sixty companies, large and small, British and foreign owned, all seeking profitably to devise, make and sell reliable drugs and medicines that will help the doctor to cure, prevent or at least alleviate disease.
I recognize that in saying this I am excluding all elements of the distributive process, but the field of my enquiry must be limited and I therefore propose to concern myself exclusively with companies undertaking research and production as well as marketing and selling.
Whatever definition of the pharmaceutical industry is adopted, it tells us little about the dayto-day working of the units which comprise it. It is what it does and how it does it and, as my purpose is to give you some insight'into the problems with which we in this industry have to deal, I pass immediately to a consideration of some of the most important of them. I do not propose to offer a reasoned explanation of all that happens in this industry, but rather to describe what seem to me to be the basic problems that have to be solved in practical terms, whatever assumptions are made about the political and economic background.
In medicine and pharmacy, as in all things, there has to be a beginning and there is no more logical point of departure in pharmaceutical industry than research and development: research designed to discover a new compound with desirable clinical properties, and development designed to make its production feasible on whatever may be the appropriate scale of manufacture.
Research Activity There is commonly much misunderstanding about the nature of pharmaceutical research. The industry is sometimes reproached with never having discovered anything of basic and fundamental importance and is sometimes accused of concerning itself unduly with the duplication and reduplication of clinical effects by molecular analogy.
The economics of private enterprise, and it is a private enterprise process with which we are concerned, provide an adequate theoretical justification for profits, and even a more than average level of profits, for risk-taking. One of the more obvious forms of risk-taking in pharmaceutical industry resides in the sustained expenditure of money on research and development. Recent statistics suggest that this expenditure in the United Kingdom has already passed £8,000,000 and must now be approaching £10,000,000 per annum. Research expenditure in pharmaceutical industry abroad far exceeds that in the UK and the total resources devoted to this end in the Western World are today probably of the order of £100,000,000 per annum. Notwithstanding the industry's evident willingness to spend considerable sums of money in this way, it must be admitted that the proportion of it laid out on basic 'and fundamental problems is and must be limited. Uncertainty about the outcome of fundamental research is such that no company could afford to devote the whole, or even a large proportion of its research outlay to this end. No one has yet devised a method, first of identifying a future Fleming or a future Pasteur, and then securing that he preferentially finds himself in industrial employment at the time of his maximum inventive output. Though pharmaceutical companies do support fundamental research it is just as likely to be organized outside the firm as in it, and its amount controlled by a purely pragmatic judgment of the proportion of the company's available resources that can be ventured speculatively in a field where the odds are heavily against success.
In parenthesis, it may be noted that, though these highly speculative projects are limited in extent, they are often maintained for considerable periods in the face of repeated disappointments. Indeed there must be a Parkinson Law which holds that if such a project succeeds in surviving three years its chances of a ripe old age are great, and if it survives seven years, then only the death of the research worker involved or the failure of the financing company will bring it to an end! Thus a pharmaceutical company's research and development expenditure is more likely to be concerned with the no less essential task of translating into therapeutically effective products basic ideas of very diverse origins. Perhaps one of the, most impressive examples of the process in action is provided by the history of penicillin development. You are all familiar with the work of Fleming and subsequently of Florey and' his co-workers that provided in 1940 the first clinical demonstration of the probable medicinal value of the crude extracted metabolite of Penicillium notatum. What perhaps is not so well known is the immense amount of money that was subsequently spent by pharmaceutical companies both here and, more importantly, during the Second World War in the USA, in bringing'to bear upon the task of making large quantities of penicillin for wartime use, the techniques of large scale production and the special technology of industrial deep fermentation. The whole of the subsequent history of the development of penicillins is in very large measure the history of pharmaceutical research and development, financed and carried through to a successful conclusion by industrial companies. Indeed, with one or two exceptions such as the work of Waksman on streptomycin and of Florey on cephalosporin, practically the whole of the subsequent history of the antibiotics is closely bound up with and depends for its shape and productivity on industrial resources. It would be unfortunate if by this choice of example I should give the impression that the history of pharmaceutical research and development began during the war years of 1939 to 1945. At the time of the discovery of insulin by Banting and Best in December 1921 the comment was widely made that this was an interesting discovery but of little practical importance to sufferers of diabetes. Yet within eighteen months insulin was made commercially available. Further research and development has gone on in this field ever since, leading to varieties of insulin particularly suited'to differing groups ofcases becoming available at steadily reducing cost.
The same is true of developments in sulphonamide and corticosteroid theratpy. The original products had definite and well-recogniized disadvantages which were only 'acceptable -in medical practice because of the significant and far outweighing advantages in the treatment of conditions previously escaping effective medication. Here again industrially financed research and development expenditure successfully provided improved products of lower toxicity and of greater-and more selective activity.
In a very superficial sense many of these products which in the particular field have succeeded one another might be regarded as merely molecular variants of their predecessors, but in retrospect it is obvious that the outcome has been a great improvement in the products available for medical use which could not have been realized in any other manner.
Both as a cause and as an effect of this research activity, individual firms have built up over the years a valuable and highly valued 'capacity to resolve problems in fields in which they have made themselves especially knowledgeable. The result is today that the delays attendant upon the translation into practical results of any new knowledge are much reduced and the speed with which larger quantities, if required, can be produced at lower cost is much increased.
Development Economics
At this point I must make it clear that a research project is not completed by the identification of the new compound and its manufacture in quantities adequate for toxicity testing and the clinical demonstration of its utility. There follows a long, often tedious and invariably expensive period of development work involving subsidiary research into the best methods of manufacture and pharmaceutical enquiries to discover the preferable formulation of the product for medical use.
The acceptability of a drug is a function not only of its clinical merits but also of the pharmaceutical skills which have gone into its presentation'for oral, topical, or parenteral employment, la Library (Scientific Research) Section while sometimes even packaging considerations may play an important part in determining its convenience in use.
What, however, is even more important, both from the point of view of the scale upon which the drug can be made available and of the price at which it can ultimately be produced and sold, is the steady application over considerable periods of time of effort devoted to the improvement of manufacturing efficiencies and the enhancement of the purity of the end-product. This is just as important in the fermentation field as in the field of synthetic chemistry though one or two salient facts taken from the latter area of endeavour will make the point clear. If a new drug is the product of, say, twenty stages of manufacture in building up the desired endproduct by successive chemical reactions from its primary raw materials, it may be sufficient for research purposes initially to achieve an average efficiency at each stage of, say, 60 % even though this means an overall yield from start to finish of no more than 0 0037 %. As a manufacturing proposition this is a completely unacceptable performance and a stage target of, say, 80 % may have to be substituted as a minimum to secure an overall yield about 300 times greater at 1 15%. If, however, real efficiency is to be achieved to secure competitive costs and an adequate volume of output from often expensive raw materials a target of, say, a 20% yield over the 20 stages must be realized. This requires an average stage efficiency of over 92 % which is, to say the least of it, a very demanding proposition.
It is something which cannot be realized in a month or even a yearit is the end-product of years of work devoted to the improvement of stage operational conditions. Without this endeavour the product may conceivably remain impossibly expensive; with it output can be raised, costs progressively reduced and prices brought down.
That this is no purely theoretical concept is evidenced by the fact that eight years ago the price to the chemist of a bottle of 40 x 25 mg tablets of cortisone was 35s, whereas to-day the chemist's price for the same number of tablets of one of its more recent clinical equivalents, betamethasone, is 9s 2d. Similarly in the fermentation field fifteen years ago the price to the chemist of a 1 mega unit vial of penicillin G was 13s 4d while today it is ls 24d. It should also be borne in mind that the purchasing power of the £ has been reduced by 20% over the last eight years and by 35 % over the last fifteen years, so that over the respective periods the cost of systemic corticosteroid therapy has, at constant prices, been reduced by 78 % and of penicillin G therapy by 93 %.
Before we leave this subject it is worth reflecting for a moment on the costs of keeping in existence teams of workers able and ready to tackle problems of the kind I have referred to above.
Excluding all considerations of capital cost of buildings and equipment, a graduate operating in this field is likely to cost, with supporting services and technical help, £5,000 to £6,000 per annum, a cost which has steadily increased over the last decade and shows no signs of stabilization. For an annual expenditure of between £150,000 and £200,000 a company may reasonably hope to build up valuable research and development capacity in a restricted field that its tradition or its own initiative has indicated as worth while and relevant to its business future.
If, however, a more general, competence is aimed at with probably some specialization in chosen areas, then expenditures of ten times this amount are probable. It is indeed doubtful whether a substantial stake in the broad field of pharmaceutical research and development can be maintained for less than a continuing expenditure of over £1,000,000 per annum.
It should be noted also that commitments of this order are liable to be not only increasingly costly, but difficult of adjustment to poorer trading results without severe damage to the morale and therefore the productivity of the research team. This is in part the explanation of the disproportionately heavy expenditure on research of British houses in relation to their turnover from the National Health Service. Without an ability to draw upon the profits of trading in other pharmaceutical markets overseas and in nonpharmaceutical markets here and abroad, they would not be able to continue expenditures at the level judged necessary for even modest success. No British business in this field is able to justify its continued expenditure with reference solely to the United Kingdom demand for its drugs. Indeed, in at least two post-war cases a conscious decision was taken by management heavily to subsidize research and development expenditure from other resources.
I do not wish to give the impression that the directors of pharmaceutical industry are noncommercial philanthropists solely concerned with the advancement of medicine. It should, however, be appreciated that once a decision is taken to enter the field of pharmaceutical research certain long-term obligations immediately follow;
obligations not merely concerned with keeping research teams together and enthusiastic about current objectives, but also obligations to external scientific collaborators and government agencies all anxious to see that potential clinical values in their research are enquired into and wherever possible realized for the benefit of the community as well as for the academic honour of the inventor and the profitability of the company financing the work.
Competition
What is characteristic of the position in the United Kingdom is also characteristic of the position in other parts of the Western World where private enterprise is still the basic form of industrial organization. The result is that on the world's pharmaceutical markets outside Communist territories, there will be found some two or three dozen international houses all seeking to secure from the sales of their products, new and old, a profitable return on the capital which they have invested in plant and equipment and on the large sums which they continue to spend on research and development.
It follows from what I have described as typical of the international, as well as the national, situation that at any one time there are likely to be two (and sometimes more) companies probably in or approaching a position where they are able to make and sell a new drug to the medical profession. All of them will have spent substantial sums on research and development, all will know that more will need to be spent if its usage develops to a point where increased demand requires larger scale operation. All will have in front of them the continuing need to sustain further research and development expenditure at a high and possibly more costly level and all will guess that there may be another one or more companies temporarily out of the picture that are, however, capable of following a lead and producing an even better product within reasonable time.
Thus there will arise the urgent need to establish the new product in the market and all companies operating in the field will seek to protect their distinctive processes and products by the legitimate means of patenting and trademarking. The more competitive in a scientific sense the market becomes, the more likely are these points of protection to be sought and defended, for without them it is likely that the originating company will be unable to secure such benefits from its manufacturing and trading as will enable it to continue in business, and therefore to continue to sustain research and development expenditure at a level that will secure its future.
To those who are familiar with the medical and administrative criticism of the number of trademarks in the pharmaceutical market, and who have recently followed the course of ministerial action in the use of Section 46 of the UK Patents Act, it will come as n-o surprise that it is precisely here that much of the difficulty emerges in recon-ciling the business necessities of pharmaceutical industry with medical convenience and the administrative view of the public interest within the framework of the N.H.S. I return to these difficulties later on.
Responsibilities of Manufacturer and Doctor Safety: If one assumes, inaccurately but conveniently, that research is generally finished before the next stage is reached and, conversely, that the next stage has no effect on the content of research, then our next concern is with the safety quality and efficacy of the drugs emerging from research and development.
I am sure I do not need to prove to this audience that no drug is completely safe in all circumstances, and all will accept that the absence of toxic reactions on the administration of the drug to selected animal species does not remove the necessity for careful observation in the course of its subsequent administration to man. Indeed, safety in this context is not an absolute quality; it is the outcome of the closest co-operation between research worker and clinician, between the industrial organization and the medical profession even at the point of the representative's call upon the general practitioner in his office or surgery.
For the time being we are concerned with the stage of co-operation before a drug is sold. In various countries various methods are adopted to secure the protection of the public against the salb of dangerous drugs. As is well known the Food and Drug Administration of the USA had and still has, as one of its primary objectives, an official review of the pharmacological and clinical evidence in order to exclude from sale any substance that might be toxic to man. In practice this has meant, of course, that a code ofjudgment has been developed which tries to secure not that all new drugs sold are safe in any absolute sense, but that in the course of sale adequate notice is given to the physician of any identified side-effects or contraindications that should be borne in mind in the course of his use of the medicament.
In this country the approach has traditionally been to rely for the safety of the public on the capabilities and sense of responsibility of manufacturer and doctor. In the event of negligence the manufacturer would be faced with legal actions and a loss of medical goodwill fatal to his business and the doctor would equally find himself in an impossible professional situation if negligence were proved. As is not unusual in this country, the legislature has not been wholly consistent in its attitude towards this problem of drug safety.
Particularly within the framework of the Therapeutic Substance Acts, it-has provided for a more rigorous system of inspection and control than Library (Seientific Research) Section is the rule in the wider field of drugs based upon chemical synthesis.
The thalidomide tragedy has again focused public and professional attention on this question. It has called the attention of pharmacologists to the need for even greater refinements of technique than those hitherto in use and has redirected the attention of the doctor to the special problem of medication of the pregnant woman. The basic question, however, is still the same. Are we to rely upon the sense of responsibility both of doctor and manufacturer or are we to substitute another judgment as to what may or may not be done? I hope, and there are many in the industry and the medical profession who share the opinion, that the primary responsibility will continue to rest where it does to-day. There is room for continuous research into the techniques of testing for latent toxicity in new compounds. There is room for action to secure that all new compounds have been submitted to such further refined testing as pharmacological research results may suggest is desirable. There is room for better facilities for clinical trials of new compounds and there is room for a second opinion other than that of the manufacturer or originator of the new product in review of the available evidence before general sale of the drug is instituted. Great care must, however, be exercised to secure that judgments so formed are based upon scientifically established facts completely divorced from administrative considerations of the cost of drugs.
Nothing must be done to weaken the manufacturer's sense of responsibility for his acts, for there is no experience more testing of character and professional conscience and ability than the need to take a responsibility on the available evidence for the sale and use of a new compound. The need within the industrial pharmaceutical organization to accept responsibility at Board level goes much farther in that it is necessarily communicated to all lower levels of executive actionto the analytical and research departments, to the production units, even to the operators of the process stagesand raises both morale and standards of integrity at all points.
Very similar considerations hold good for members of the medical profession. There is no satisfactory substitute for the doctor's knowledge of the facts about the preparations he uses, for his experience in their use and for his judgment whether he will incur the risks of using something potentially dangerous but potentially useful. Penicillin was first presented commercially in this country as a freeze-dried yellow substance in a sterile ampoule, and was certainly not more than 50% pure as we understand penicillin G purity to-day. Whatever the dangers attendant upon its useand we now have, twenty years later, a better appreciation of these than ever beforethere is no doubt of the immense contribution which its introduction represented in the effective treatment of bacterial infections.
Quality: In the course of my discussion of the topic of safety I have mentioned the effects upon the elements of the industrial organization of the need for management to accept responsibility for its actions. The encouragement which this gives to the development of a pharmaceutical manufacturing competence is nowhere more evident than in the maintenance of quality in the drugs sold. It is often assumed that if a drug complies with the British Pharmacop(eia or one or other of the official books of reference and is reasonably packed, it is at least as good as it need be. If raw materials are purchased to a predetermined specification and processed to an end-product which is tested according to a schedule laid down in a monograph, it is no doubt possible to say whether, in the light of the facts disclosed, the end-product is satisfactory in a general sense. It is not, however, possible to say whether it is as good as it should be unless much more is known about the conditions under which it was produced, about the possible minor uncontrolled variations in method that may have occurred in its manufacture, about the conditions for which it will ultimately be used and the circumstances under which it will be employed. The reports of leading public analysts who have experience in the testing of drugs under the Food and Drug laws of this country are well worth careful study in this connexion. It is not possible to achieve and maintain quality in drugs without conscientious application to the job and the basic knowledge derived from previous research and development experience.
Clinical trials: Finally, in this group of considerations relevant to the testing of drugs before sale there is the question of efficacy and clinical trial. It is, of course, essential that before sale there should be established as complete a case as possible for the use of a new compound in medicine. The important questions are how this should be done and how in practical terms it can be done. There is no very satisfactory and generally accepted body of doctrine. It is a field in which much more requires to be done not only to improve the measure of agreement between individuals about what is desirable but also to improve the chances of what proves generally acceptable being carried out. The difficulties range all the way from getting schemes of sequential analysis, or double-blind experimentation, accepted by all as relevant to the determination of utility, to the impossibility of getting any work done at all on some urgent problems of seemingly little medical importance. Here we have a situation which can usefully engage the attention of all, particularly in the medical profession, who attach importance to the proper trial of new compounds before sale. Much has already been done to clear up some of the practical and theoretical issues still outstanding but progress is also needed in the field that will secure a greater volume of clinical testing with the co-operation of consultants, teachers in medical schools and general practitioners. It is important that the medical profession at large should be encouraged and provided with opportunity to take an active and indeed enthusiastic part in the large scale testing of drugs as their every action in therapeutics is a test of their judgment of what is appropriate in the individual case. If they tookincreased part in such work, their general knowledge, competence and indeed scepticism would be usefully reinforced.
We now turn to a consideration of those aspects of pharmaceutical industry which attract the most attention from the Public Accounts Committee of Parliament, from the Auditor General, from the Minister of Health and, I am led to believe, from many members of the medical profession. I refer to selling activities and the costs involved; prices and the profits made.
Pharmaceutical Advertising and
Medical Representation I should personally be somewhat happier if less material were delivered into the doctor's post bag, if fewer representatives were calling regularly on doctors and if less money were spent on advertising in professional journals, though the latter might not be very popular with their editors. I say this not because I believe it can be proved that the costs of sales promotion are excessive and certainly not because I believe that there is no call for mailed propaganda, representatives' calls or journal advertisements. I say it because it seems to me that the total amount of the doctor's time and attention it is sought to employ in this way is somewhat excessive and the result inimical to his proper consideration of those facts which he must have if he is to do his job properly. I emphasize that he must have these facts if only because his use of drugs may be dangerous if he does not take notice of proper warnings by the written or spoken word.
The whole of this problem would benefit from a thorough reconsideration by executives in the industry and doctors in practice. There is no substitute for a booklet or pamphlet mailed to each prescribing doctor if he is to be put promptly in possession of the facts about a product that he is using or likely to prescribe. It is very unfortunate, and possibly dangerous, if as a result of his receipt of substantial amounts of mail, he gets into the habit as some doctors say they do, of throwing much of their mail, sometimes unopened, into the waste paper basket.
There can be no serious objection to the industry's practice of presenting the facts in readable form that attracts rather than repels attention, for the costs of a good layout employing a good type face on good paper over the purely utilitarian alternatives is unimportant, particularly when it is borne in mind that the cost of the envelope and the postage is a common factor in all such communications.
There is I think also a justification for reminder advertising by post, though both the sender and the recipient should recognize it and indeed be able to recognize it instantly for what it isephemeral and memory jogging. It should, therefore, be of such a type as marks it out as inexpensive and expendable. If a doctor cannot rapidly and easily extract from his mail the communications from companies he knows and which he wants to read at perhaps greater leisure, then steps must be taken so to improve matters that this becomes possible. There is no place in such a system for gimmicks designed to attract the attention of the recipient under false or irrelevant pretences.
Without the substantial volume of advertising in professional journals the accounts of many medical publications would quickly be thrown into disorder, but one sometimes wonders whether the content of the advertisement pages is really worth while, particularly when eye-catching layouts and illustrations either swamp the message it is intended to convey or engender reader resistance by reason of their irrelevance.
With medical representation one is back again in the more contentious field of demands made directly upon the doctor's time.
Such evidence as is available suggests that the average doctor welcomes or would welcome the visit at fourto six-monthly intervals of a welltrained representative from a house whose products he uses and respects. What is objected to more often than not is the seemingly increasing number of these calls in circumstances which may not always be convenient by individuals whose abilities are limited to the presentation of predigested facts. The depreciation in the quality of the medical interview which inevitably results is a loss to both doctor and industry. If the interview is not a worth-while exchange of views and facts about a product between the user or potential user and a pharmaceutically qualified representative, it is not fulflling its legitimate purpose and in the long term is a waste of medical and pharmaceutical abilities.
In this matter, as in that of medical mailed propaganda, the doctor himself has a very active part to play. He can by his own actions largely condition the climate of opinion and dictate to the industry the methods it must adopt to be acceptable. There is no compulsion upon him to continue to receive literature that he does not want from firms whose products he does not use, for at least the members of the Association of British Pharmaceutical Industry have pledged themselves to remove his name from their mailing lists if he so requests. Similarly the doctor is under no compulsion to see every representative who calls and a selective welcome for the better men will in time exclude the poorer from circulation.
Prices andProfits in the Pharmaceutical Industry This problem, at least in this country, is closely connected with the existence of a National Health Service. One must, however, bear in mind the increase in the use of medical specialties and the decline in the prescription of the more traditional generic or formulary preparations, which characterize all similar situations here and overseas.
The introduction of the N.H.S. has, of course, brought immense benefits but it has also one great disadvantage in that it has weakened, if not eliminated, that close contact between doctor and manufacturer which was not only a considerable benefit to both but also provided a check or rather a running criticism from the doctor of price in relation to his patient's ability to pay. A highpriced yet worth-while product might in the prewar period find initially a restricted market through consultants, while at a lower price it could hope to be prescribed more freely in the middle class suburbs, and at even lower prices still could achieve a larger market by prescription in the industrial areas of London and the Provinces. A preparation of utility would find its market further expanded by sales at near cost to the voluntary hospitals into which it was often introduced by the consultants who were responsible for its first prescription. This background accorded well enough with the inescapable facts of industrial pharmacy. The first restricted quantities of a new drug are inevitably costly, and these costs are only reduced by the economies that come with larger scale manufacture and through the application of development effort to improve efficiencies made necessary and worth while by the emerging larger demand. Today these same basic facts of cost in relation to scale of production still hold true and are reinforced by the changing nature of the new preparations coming on to the market.
The typical product of the pre-war period was the animal or vegetable extractive or the relatively simple synthetic chemical. The typical product of the post-war period is the much more complex synthetic product or the outcome of highly specialized industrially controlled biological processes. The result is that the first cost is necessarily high and a relatively large demand is required to justify the cost of development expenditure to improve stage efficiencies without which lower costs and, therefore, lower prices will not be realized. If the features which I have earlier referred to in the discussion of research activity are borne in mind, it will readily be appreciated that the new drug today comes into being against a background of all round higher costs not simply because the value of the pound has been much reduced compared with the pre-war period but because the cost elements have moved into a new dinmension.
Nevertheless it is still true that lower costs of production can be and are regularly achieved with increasing scale of demand and it is further important to realize that the N.H.S. has removed many of the obstacles previously existing to the wider prescription of the valuable new product. The doctor no longer as a matter of primary concern has to consider the cost to the patient of what he wants to prescribe, but it is of increasing concern to the State which now meets the prescription bill in full that there should be some continuous administrative criticism of price. It is particularly to be regretted that in this situation, which is really a profession-and-industry-wide variant of the pre-war state of affairs, the bulk of the public criticism of pharmaceutical prices and profits should have come from those who know least about medicine and pharmacy. Professional opinion is only brought to bear through advisory committees deficient in representation of industry and sometimes relatively deficient in contacts with the general practitioner and the dispensing chemist.
If to-day we have escaped from the more or less automatic controls of the pre-war open market economy, one would hope that Government, in the new position where it is called upon to create a framework within which prices and values may be reasonably determined, would seek closely to associate representatives of industrial pharmacy both with the formation of policy and with its execution. If industry is not given the responsibility that goes with the power that the development of technology has thrust into its hands, it will not be surprising if the latter is wielded more with a nice regard for protocol than with a full appreciation of wider interests and considerations. The same seems to me true also of the medical profession. Largely deprived of any contact with or concern for costs of dispensing and no longer for the most part concerned whether the patient can pay for what is prescribed, their faculty of assessing. value for money has atrophied, but their power to wreck the calculations of the Minister of Health of his probable costs of N.H.S. prescribing has greatly.increased.
For the reasons already given it is unlikely that in any worth-while degree the total cost of drugs supplied through the N.H.S. will be reduced and indeed, without inflation, the total expense will have an inbuilt tendency to increase. Recent publications of the Office of Health Economics have indicated that the introduction of a new medicament, coupled with other measures, the effect of which is often not readily separable, creates values expressible in terms of Gross National Product, Wealth and Welfare. But it is obviously not true that the nation as a whole is prepared to pay any sum to roll back by months or even years the date of the inevitable end.
Thus there has to be a limit, no doubt from time to time a variable limit, set to what the Nation can and will afford for the drug component of its National Health Service. Until the pharmaceutical. industry, and for that matter general practitioners and dispensing chemists, are recognized as essential contributors to that service, sharing responsibility as well as power, any solution temporarily reached is likely in the long run to prove unsatisfactory and lie at the mercy of critical minds unconcerned with and indeed often unaware of the basic problems of 'medical prescribing and pharmaceutical innovation.
I am very conscious that in this paper I have had to pass rapidly in review numerous topics some of which could be and indeed have been the subject of a lecture or a'whole day's symposium in their own right. I have endeavoured to give some idea and perhaps a better appreciation of how the pharmaceutical industry works. I shall be more than satisfied if I have suggested a thoughtor line of action that can be usefully developed for the benefit of what we all in the last analysis have most at heart, the health and welfare of our fellow citizens.
